Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354036 | 0.90 | INPPL1 (0.43) | INPPL1NPSR1ADRB2THRATHRB | |
| SCHEMBL12313590 | 0.89 | INPPL1 (0.55) | INPPL1NPSR1KDM4ENSD2ALDH1A1 | |
| SCHEMBL12337537 | 0.88 | INPPL1 (0.51) | INPPL1NPSR1ALDH1A1INPP5A | |
| SCHEMBL12337367 | 0.85 | CYP3A4 (0.41) | INPPL1ADRB2ALDH1A1 | |
| SCHEMBL2351412 | 0.85 | INPPL1 (0.53) | INPPL1ADRB2THRATHRBKDM4E | |
| SCHEMBL12313586 | 0.84 | INPPL1 (0.49) | INPPL1NPSR1THRATHRBKDM4E | |
| SCHEMBL2469681 | 0.81 | IRAK4 (0.37) | INPPL1ALDH1A1IRAK4STK17BINPP5A | |
| SCHEMBL2463713 | 0.81 | MAOB (0.43) | NPSR1ADRB2PKMMAOB | |
| SCHEMBL12313531 | 0.80 | PKM (0.48) | NPSR1ADRB2PKMMAOB | |
| SCHEMBL12337231 | 0.79 | INPPL1 (0.59) | INPPL1ALDH1A1SMN1; SMN2INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348859-B1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| EP-2348859-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010039474-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | INPPL1 1753/4885NPSR1 3083/4885ADRB2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.